Our latest Investing Matters Podcast episode with QuotedData's Edward Marten has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick pickshVIVO Regulatory News (HVO)

Share Price Information for hVIVO (HVO)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 29.50
Bid: 28.50
Ask: 29.50
Change: 0.00 (0.00%)
Spread: 1.00 (3.509%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 29.50
HVO Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

hVIVO and Imutex to present at IVW 2019

29 Mar 2019 07:00

RNS Number : 3748U
hVIVO plc
29 March 2019
 

hVIVO plc

("hVIVO" or the "Company")

 

hVIVO and Imutex Limited to present at the Influenza Vaccines for the World (IVW 2019) conference at the Royal College of Physicians of Edinburgh, Scotland

 

London, UK 29 March 2019: hVIVO plc (AIM: HVO), an industry leading clinical development services business pioneering human disease models based upon viral and allergen challenge, confirms that the Company and its joint venture, Imutex Limited, will present at the Influenza Vaccines for the World (IVW 2019) conference on 2-4 April 2019 at the Royal College of Physicians of Edinburgh, Edinburgh, Scotland, UK.

 

IVW 2019 is an international conference and exhibition in an important series of influenza vaccine meetings focused on 'Influenza Vaccination Issues'. The IVW series is an international forum for world renowned experts in the field of influenza vaccines and related issues (adjuvants / delivery / vaccination strategies) to report on the latest data and trends associated with current and new influenza vaccines / technologies and their availability / delivery / implementation worldwide.

 

Presentation details are as follows:

 

Title: FLU-v, a broad spectrum influenza vaccine: cross-reactivity and field results

Presenter: Dr Olga Pleguezuelos, Imutex (SEEK)

Date and time: Tuesday, 2 April 2019, Session 3,12.10-12.40

Location: Royal College of Physicians of Edinburgh, Scotland, UK

 

Title: The future for FLU-v: Efficacy results from an H1N1 challenge study

Presenter: Dr Emma James, Imutex (SEEK)

Date and time: Tuesday, 2 April 2019, Session 4, 14.30-15.00

Location: Royal College of Physicians of Edinburgh, Scotland, UK

 

Title: The human viral challenge and the evaluation of novel/universal vaccines

Presenter: Dr Rob Lambkin-Williams, hVIVO

Date and time: Wednesday, 3 April 2019, Session 6, 09.30-09:50

Location: Royal College of Physicians of Edinburgh, Scotland, UK

 

 

For further information please contact:

 

hVIVO plc

 

 

Trevor Phillips (Executive Chairman)

+44 207 756 1300

 

Fleur Wood (EVP, Investor Relations & Communications)

 

 

 

Numis Securities Limited

 +44 207 260 1000

 

Michael Meade / Freddie Barnfield (Nominated Adviser)

 

 

James Black / Michael Burke (Corporate Broking)

 

 

 

 

 

FTI Consulting

 

 

Simon Conway / Victoria Foster Mitchell

+44 203 727 1000

 

 

 

About FLU-v - a Phase III enabled, broad spectrum stand-alone, universal influenza vaccine candidate:

 

FLU-v is a novel first-in-class, broad spectrum, true stand-alone, influenza vaccine candidate. FLU-v is designed to provide broad spectrum cover against multiple influenza strains and does not require annual immunisation alongside an annual influenza vaccine to confer immunity. It is also designed to minimise the impact of the influenza virus by reducing symptoms, potentially relegating influenza to a much milder disease by stimulating an immune response mediated through T-cells and B-cells to the internal proteins, in contrast to seasonal influenza vaccines that prevent infection through antibody protection against external proteins. In 2017, there were two FLU-v Phase IIb studies conducted- 003 (field study) and 004 (human viral challenge study).

 

FLU-v is a synthetic polypeptide vaccine which means that it is not reliant on traditional manufacturing techniques with inherent risks, in particular the potential of a mismatch of virus particularly relevant for a pandemic strain. FLU-v is designed to protect against a broad range of influenza viral strains and this includes unexpected seasonal strains or a potentially devastating pandemic strain.

 

FLU-v is being developed by Imutex Limited, hVIVO's 49% joint venture with PepTcell Limited, trading as the SEEK Group ("SEEK").

 

About hVIVO:

 

hVIVO plc ("hVIVO") is pioneering a human-based clinical trial platform to accelerate drug and vaccine development in respiratory and infectious diseases. Leveraging human disease models in flu, RSV, HRV and respiratory indications, the hVIVO platform captures disease in motion, illuminating the entire disease life cycle from healthy to sick and back to health. Based in the UK, market leader hVIVO has conducted more than 50 clinical studies and inoculated over 2500 volunteers.

 

 

About SEEK Group (PepTCell Limited, trading as SEEK Group):

 

SEEK's strategy is to bring safe, effective and low-cost medicines to patients as quickly as possible, to radically improve human health in major disease areas.

 

We do this by:

 

· Modifying existing medicines to improve their efficacy

· Using existing medicines in new indications

· Creating new chemical entities

 

Working in these different ways allows us to optimise the regulatory approval pathway to ensure that we bring safe and effective products to patients in the shortest possible time.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
NRAPGUBGWUPBGAR
Date   Source Headline
27th Mar 20247:00 amRNSNotice of Results
22nd Mar 20243:03 pmRNSHolding(s) in Company
14th Mar 20247:00 amRNSHolding(s) in Company
15th Feb 20247:00 amRNSLong Term Incentive Plan / PDMR Notification
14th Feb 20241:14 pmRNSResult of Secondary Placing
14th Feb 20247:00 amRNSProposed Secondary Placing of Ordinary Shares
2nd Feb 202412:44 pmRNSHolding(s) in Company
30th Jan 20247:00 amRNSTrading update
8th Jan 20247:00 amRNSBroker change
2nd Jan 20247:00 amRNS£6.3m HRV contract signed with biotech client
13th Dec 20237:00 amRNS£16.8m RSV contract & Trading ahead of guidance
5th Oct 20237:00 amRNSPositive results from flu human challenge study
12th Sep 20237:00 amRNSInterim results
1st Sep 20237:00 amRNSExercise of Warrants
29th Aug 20237:00 amRNSPlans for a new larger state-of-the-art facility
24th Aug 20237:00 amRNSNotice of Results
26th Jul 20237:00 amRNSTrading update
25th Jul 20237:00 amRNSFlu B challenge model
28th Jun 20237:00 amRNShMPV human challenge model
14th Jun 20238:00 amRNSDirector dealings
23rd May 202312:36 pmRNSResult of AGM
28th Apr 20237:00 amRNSAnnual Report and Notice of AGM
26th Apr 20237:00 amRNSFDA Breakthrough and Fast Track for US biotech
25th Apr 20237:00 amRNSFinal results
19th Apr 20237:10 amRNSNotice of Results
6th Apr 20233:54 pmRNSHolding(s) in Company
3rd Apr 20237:00 amRNSPositive results from flu human challenge study
29th Mar 20237:00 amRNSPresentation at World Vaccine Congress
23rd Mar 20237:00 amRNSExercise of Options
16th Mar 20237:00 amRNSOmicron human challenge model update
6th Feb 20239:05 amRNSSecond Price Monitoring Extn
6th Feb 20239:00 amRNSPrice Monitoring Extension
6th Feb 20237:05 amRNSLong Term Incentive Plan / PDMR Notification
6th Feb 20237:00 amRNS£6.8m RSV human challenge contract signed
25th Jan 20239:06 amRNSSecond Price Monitoring Extn
25th Jan 20239:00 amRNSPrice Monitoring Extension
25th Jan 20237:00 amRNSTrading update
17th Jan 20237:00 amRNSEUR3.2m Venn contract with global pharma client
4th Jan 20234:40 pmRNSSecond Price Monitoring Extn
4th Jan 20234:35 pmRNSPrice Monitoring Extension
4th Jan 20237:00 amRNS£5.2m RSV contract and Notice of Trading update
3rd Jan 20234:40 pmRNSSecond Price Monitoring Extn
3rd Jan 20234:35 pmRNSPrice Monitoring Extension
3rd Jan 20232:05 pmRNSSecond Price Monitoring Extn
3rd Jan 20232:00 pmRNSPrice Monitoring Extension
3rd Jan 202311:05 amRNSSecond Price Monitoring Extn
3rd Jan 202311:00 amRNSPrice Monitoring Extension
19th Dec 20227:00 amRNSImutex Phase I data published
17th Nov 20222:05 pmRNSSecond Price Monitoring Extn
17th Nov 20222:00 pmRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.